Archive


Category: Baxter

  • PharmaShots’ Key Highlights of Third Quarter 2021

    The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B, […]

  • PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

    Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis Pfizer […]

  • PharmaShots Weekly Snapshots (August 30 – September 03, 2021)

    Forte’s FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis Pfizer […]

  • Baxter to Acquire Hillrom for ~$10.5B

    Shots: Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s closing price of $124 and a total enterprise value of ~ $12.4B, including the assumption of debt. The acquisition is expected to be closed in early 2022 The acquisition will […]

  • Baxter in Talks to Acquire Hill-Rom for ~$10B

    Shots: Baxter in talks to acquire Hill-Rom for ~$10B with $150/ share representing a premium of 13% to the stock’s closing price of $132.90. The acquisition is expected to be announced later this week The decision follows an earlier bid in which Hill-Rom had turned down Baxter’s previous offer of $144/ share with a total […]

  • Top 20 Medical Device Companies Based on 2020 Revenue

    The medical devices industry is a fast-growing market driven by the complex needs of patients encouraging life science companies to develop innovative therapies to improve health and QoL In 2020, the companies have shown growth resulted from a rise in the number of healthcare facilities, healthcare expenditure, technological advancements. Medtronic remains at the top of […]

  • PharmaShots Weekly Snapshot (Nov 23 – 27, 2020)

    Merck Collaborates with Siemens for the Digitalization of Production Published: Nov 26, 2020 | Tags: Agreement, Collaborative, Digitalization, Merck, Siemens, Sign CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test Published: Nov 26, 2020 | Tags: approval, CDSCO, Co-Diagnostics JV CoSara, COVID-19 2-gene multiplex RT-PCR, India, Manufacture, receives, Saragene, Sell, Test PostEra Collaborates […]

  • Baxter and Ayogo Expand their Partnership to Advance Digital Health Solution for Home Dialysis

    Shots: The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure Baxter made an equity investment […]